Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy
作者： Ming-Yii Huang , Joh-Jong Huang , Chun-Ming Huang , Chih-Hung Lin , Hsiang-Lin Tsai
DOI: 10.1007/S00268-017-4070-Z
关键词: Pathology 、 ERCC2 、 Oncology 、 XRCC1 、 FOLFOX 、 Colorectal cancer 、 Chemoradiotherapy 、 Tumor Regression Grade 、 Medicine 、 ERCC1 、 Internal medicine 、 Cancer
摘要: Platinum resistance enhances DNA damage repair through nucleotide excision mechanisms involving the cross-complementing group 1 (ERCC1), X-ray (XRCC1), and 2 (ERCC2). We evaluated correlation between expression of these three genes clinical outcomes in patients with rectal cancer receiving FOLFOX-based preoperative chemoradiotherapy (CRT). Using immunohistochemistry, we examined ERCC1, ERCC2, XRCC1 pre-CRT tissues from 86 who had undergone curative resection CRT FOLFOX-4 to identify potential predictors outcomes. Following CRT, 57 29 were classified as responders (pathological tumor regression grade TRG 0 1) poor (TRG 3), respectively. The multivariate analysis revealed that ERCC1 overexpression was correlated a response [p 5 ng/mL) (p = 0.03; OR 6.288; 95% CI 1.198–33.006) independent postoperative relapse. By contrast, ERCC2 did not play predictive roles analyzed patients. ERCC1 is associated CRT. biomarker for identifying can benefit customized treatment programs.
springer.com
sci-hub.se 参考文章(60)
Katherine V Ferry, Thomas C Hamilton, Steven W Johnson, Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells Biochemical Pharmacology. ,vol. 60, pp. 1305- 1313 ,(2000) , 10.1016/S0006-2952(00)00441-X
Manfred F. Rajewsky, Rolf Müller, DNA Repair and the Cell Cycle as Targets in Cancer Therapy The Cancer Handbook. ,(2005) , 10.1002/0470025077.CHAP97
TNM classification of malignant tumours Published in <b>2010</b> in Chichester, West Sussex, UK ;Hoboken, NJ by Wiley-Blackwell. ,(1987) , 10.1007/978-3-642-82982-6
Frédéric Coin, Jean-Christophe Marinoni, Carlo Rodolfo, Sébastien Fribourg, Antonia Maria Pedrini, Jean-Marc Egly, Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nature Genetics. ,vol. 20, pp. 184- 188 ,(1998) , 10.1038/2491
R Metzger, C G Leichman, K D Danenberg, P V Danenberg, H J Lenz, K Hayashi, S Groshen, D Salonga, H Cohen, L Laine, P Crookes, H Silberman, J Baranda, B Konda, L Leichman, ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. Journal of Clinical Oncology. ,vol. 16, pp. 309- 316 ,(1998) , 10.1200/JCO.1998.16.1.309
Claus Rödel, Ullrich Graeven, Rainer Fietkau, Werner Hohenberger, Torsten Hothorn, Dirk Arnold, Ralf-Dieter Hofheinz, Michael Ghadimi, Hendrik A Wolff, Marga Lang-Welzenbach, Hans-Rudolf Raab, Christian Wittekind, Philipp Ströbel, Ludger Staib, Martin Wilhelm, Gerhard G Grabenbauer, Hans Hoffmanns, Fritz Lindemann, Anke Schlenska-Lange, Gunnar Folprecht, Rolf Sauer, Torsten Liersch, German Rectal Cancer Study Group, None, Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial The Lancet Oncology. ,vol. 16, pp. 979- 989 ,(2015) , 10.1016/S1470-2045(15)00159-X
Ming‐Yii Huang, Hsiang‐Lin Tsai, Chih‐Hung Lin, Ching‐Wen Huang, Cheng‐Jen Ma, Chun‐Ming Huang, Chee‐Yin Chai, Jaw‐Yuan Wang, None, Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy. Journal of Surgical Oncology. ,vol. 108, pp. 457- 464 ,(2013) , 10.1002/JSO.23422
Linda Ferrari, Alessandro Fichera, Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer Gastroenterology Report. ,vol. 3, pp. gov039- 288 ,(2015) , 10.1093/GASTRO/GOV039
David A Weaver, Erin L Crawford, Kristy A Warner, Fadel Elkhairi, Sadik A Khuder, James C Willey, ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines Molecular Cancer. ,vol. 4, pp. 18- 18 ,(2005) , 10.1186/1476-4598-4-18
E. Reed, Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treatment Reviews. ,vol. 24, pp. 331- 344 ,(1998) , 10.1016/S0305-7372(98)90056-1